This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Articles for Residents  • Glaucoma  • Alert me on articles by topic

Ramanjit Sihota, MD, FRCS; Rohit Saxena, MD; H. C. Agarwal, MD; Vikas Gulati, MD

Arch Ophthalmol. 2004;122:185-189.

Objective  To compare latanoprost and timolol maleate as primary therapy in 60 eyes with chronic primary angle-closure glaucoma after a laser iridotomy.

Methods  We performed a prospective, randomized, crossover study of 60 eyes of 30 patients with chronic primary angle-closure glaucoma after laser iridotomy. Patients were randomized to 2 groups: those taking latanoprost once daily or those taking timolol twice daily. Three months after treatment with the first drug, the second drug was substituted. The circadian rhythm of intraocular pressure (IOP) was recorded before the start of therapy, at 3 months, and at 7 months. The fourth month was the washout period for the first drug.

Results  The mean baseline IOP was 23.5 ± 2.1 mm Hg, which decreased by 8.2 ± 2.0 mm Hg with latanoprost (P<.001) and by 6.1 ± 1.7 mm Hg with timolol (P = .01). The decrease in IOP was greater for patients taking latanoprost (P<.001). Latanoprost was significantly more effective in eyes having morning and afternoon peaks of IOP. A total of 43 eyes (72%) of patients taking latanoprost and 26 (43%) on timolol achieved a reduction of more than 30% from baseline IOP.

Conclusion  There were greater mean and peak IOP reductions achieved with 0.005% latanoprost once daily compared with 0.5% timolol twice daily.

From the Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. The authors have no relevant financial interest in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review
Hodge et al.
Br. J. Ophthalmol. 2008;92:7-12.
ABSTRACT | FULL TEXT  

The Effects of Prostaglandin Analogues on Prostanoid EP1, EP2, and EP3 Receptor-Deficient Mice.
Ota et al.
IOVS 2006;47:3395-3399.
ABSTRACT | FULL TEXT  

In Vitro Study of Inflammatory Potential and Toxicity Profile of Latanoprost, Travoprost, and Bimatoprost in Conjunctiva-Derived Epithelial Cells
Guenoun et al.
IOVS 2005;46:2444-2450.
ABSTRACT | FULL TEXT